These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 8235617)
21. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Coffin JM Science; 1995 Jan; 267(5197):483-9. PubMed ID: 7824947 [TBL] [Abstract][Full Text] [Related]
22. [The chemical therapy of HIV infections. Strategies, results, prospects]. Eşanu V Rev Roum Virol; 1992; 43(3-4):221-66. PubMed ID: 1308434 [No Abstract] [Full Text] [Related]
23. The George M. Kober lecture. Basic immunology: the path to the delineation of the immunopathogenic mechanisms of HIV infection. Fauci AS Trans Assoc Am Physicians; 1988; 101():clx-clxxiii. PubMed ID: 2908369 [No Abstract] [Full Text] [Related]
24. T lymphocytes and their cytokines in human immunodeficiency virus (HIV) infection: implications for associated neoplasias. Jassoy C; Walker BD Crit Rev Oncog; 1995; 6(3-6):275-89. PubMed ID: 9012587 [TBL] [Abstract][Full Text] [Related]
25. How does HIV cause AIDS? Weiss RA Science; 1993 May; 260(5112):1273-9. PubMed ID: 8493571 [TBL] [Abstract][Full Text] [Related]
26. Present status and future prospects for HIV therapies. Johnston MI; Hoth DF Science; 1993 May; 260(5112):1286-93. PubMed ID: 7684163 [TBL] [Abstract][Full Text] [Related]
27. Therapy of AIDS patients--classical strategies and proposals for novel therapeutic approaches (a short review). Minárovits J; Berencsi G; Nász I; Földes I Acta Microbiol Hung; 1988; 35(4):361-70. PubMed ID: 3072823 [No Abstract] [Full Text] [Related]
28. AIDS pathogenesis: from models to viral dynamics in patients. Nowak MA J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S1-5. PubMed ID: 8595501 [TBL] [Abstract][Full Text] [Related]
35. Toward an understanding of the correlates of protective immunity to HIV infection. Haynes BF; Pantaleo G; Fauci AS Science; 1996 Jan; 271(5247):324-8. PubMed ID: 8553066 [TBL] [Abstract][Full Text] [Related]
36. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Marlink R; Kanki P; Thior I; Travers K; Eisen G; Siby T; Traore I; Hsieh CC; Dia MC; Gueye EH Science; 1994 Sep; 265(5178):1587-90. PubMed ID: 7915856 [TBL] [Abstract][Full Text] [Related]
37. [Pathogenicity of human immunodeficiency virus (HIV)]. Kurimura K Uirusu; 1991 Dec; 41(2):77-84. PubMed ID: 1810087 [No Abstract] [Full Text] [Related]
38. Inducing viral immunity without a vaccine--possible use with human immunodeficiency virus. Stone OJ Med Hypotheses; 1993 Feb; 40(2):95-6. PubMed ID: 8455482 [TBL] [Abstract][Full Text] [Related]
39. The role of phenotyping and replication capacity in anti-HIV therapeutics. Baliga CS; Sutton RE Curr Opin Mol Ther; 2004 Jun; 6(3):308-17. PubMed ID: 15264434 [TBL] [Abstract][Full Text] [Related]
40. Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS). Roy S; Wainberg MA J Leukoc Biol; 1988 Jan; 43(1):91-7. PubMed ID: 3275735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]